Business Description
RxSight Inc
NAICS : 339112
SIC : 3845
ISIN : US78349D1072
Description
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.05 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.52 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.96 | |||||
| Beneish M-Score | -2.28 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 29.5 | |||||
| 3-Year EBITDA Growth Rate | 41.2 | |||||
| 3-Year EPS without NRI Growth Rate | 72.1 | |||||
| 3-Year FCF Growth Rate | 44.8 | |||||
| 3-Year Book Growth Rate | 11.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 20.14 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.05 | |||||
| 9-Day RSI | 37.04 | |||||
| 14-Day RSI | 38.35 | |||||
| 3-1 Month Momentum % | -39.37 | |||||
| 6-1 Month Momentum % | -55.53 | |||||
| 12-1 Month Momentum % | -73.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.68 | |||||
| Quick Ratio | 11.65 | |||||
| Cash Ratio | 10.08 | |||||
| Days Inventory | 184.41 | |||||
| Days Sales Outstanding | 65.78 | |||||
| Days Payable | 46.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.9 | |||||
| Shareholder Yield % | -22.91 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.87 | |||||
| Operating Margin % | -24.85 | |||||
| Net Margin % | -17.9 | |||||
| EBITDA Margin % | -15.64 | |||||
| FCF Margin % | -13.83 | |||||
| ROE % | -10.39 | |||||
| ROA % | -9.28 | |||||
| ROIC % | -64.88 | |||||
| 3-Year ROIIC % | 34.95 | |||||
| ROC (Joel Greenblatt) % | -51.05 | |||||
| ROCE % | -10.01 | |||||
| Years of Profitability over Past 10-Year | 2 | |||||
| Moat score | 3 | |||||
| Tariff score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 37.54 | |||||
| PS Ratio | 3.51 | |||||
| PB Ratio | 1.91 | |||||
| Price-to-Tangible-Book | 1.91 | |||||
| EV-to-EBIT | -11.94 | |||||
| EV-to-Forward-EBIT | -7.59 | |||||
| EV-to-EBITDA | -13.62 | |||||
| EV-to-Forward-EBITDA | -10.11 | |||||
| EV-to-Revenue | 2.13 | |||||
| EV-to-Forward-Revenue | 1.95 | |||||
| EV-to-FCF | -15.39 | |||||
| Price-to-GF-Value | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 2.1 | |||||
| Price-to-Net-Cash | 2.73 | |||||
| Earnings Yield (Greenblatt) % | -8.38 | |||||
| FCF Yield % | -3.84 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers